
THE LMGM-CBI IS PARTICIPATING TO THE NEW INDO-FRENCH INTERNATIONAL RESEARCH NETWORK (IRN) MIRA

The new International Research Network (IRN) MIRA (Maladies Infectieuses émergentes et Résistance aux Antibiotiques / Emerging Infectious Diseases and Antibiotic Resistance) brings together 4 French and 5 Indian partners (see details below) who will join forces in the fight against emerging infectious diseases and antimicrobial resistance. This new IRN was selected by the INSB in 2022 (11 laureates out of 21 applications) for a 5-year funding (2023-2027). This is the 13rd IRN supported by the INSB.

In a context of unprecedented changes in human-environment interactions and increasing disruption of ecosystems and climate, creating a particularly favourable context for the emergence of infectious diseases, the worldwide spread of (multi-)antibiotic resistant bacteria represents a major short-term threat to global health. It is therefore essential and urgent to strengthen our efforts to put in place all the necessary means for prevention, surveillance and response to emerging infectious diseases and antibiotic resistance.

By combining their strengths and complementary resources, the 9 partners of the MIRA network share the common objective of strengthening their research and innovation capacities, from the most fundamental research to applied research for the discovery of new therapeutic and preventive approaches against pathogenic bacteria, through an international collaborative approach.

The partners will endeavour to structure and develop the various areas of cooperation identified and to implement the various levers to perpetuate their joint efforts in favour of global health. The programme will include the organisation of trans-national events for the sharing of knowledge, tools and expertise, as well as exchanges of staff, in particular students and post-doctoral fellows.

French Partner 1 and Coordinator: Dr. Olivier Neyrolles Institute of Pharmacology and Structural Biology (IPBS Toulouse, <http://www.ipbs.fr/>) - CNRS/University of Toulouse, Paul Sabatier

Partner 2: Dr. Patrice Polard and Dr. Nathalie Campo Laboratoire de Microbiologie et Génétique Moléculaires - Centre de Biologie Intégrative (LMGM-CBI, <https://cbi-toulouse.fr/eng/>) - CNRS/University of Toulouse, Paul Sabatier

Partner 3: Prof. Eric Oswald Digestive Health Research Institute (IRSD, <http://en.irsd.fr/>) - Inserm/INRAE/ENVT/ University of Toulouse, Paul Sabatier

Partner 4: Prof. Pierre Delobel and Prof. Guillaume Martin-Blondel Toulouse Institute for Infectious and Inflammatory Diseases (INFINITY, <https://www.infinity.inserm.fr/en/>) - Inserm/CNRS/ University of Toulouse, Paul Sabatier

Indian Partner 1 and co-Coordinator: Prof. Amit Singh Indian Institute of Science of Bangalore (IISc, <https://iisc.ac.in/>)

Partner 2: Dr. Vinay K. Nandicoori Centre for Cellular & Molecular Biology of Hyderabad (CCMB, <https://www.ccmb.res.in/>) - CSIR



Partner 3: Prof. Anjana Badrinarayanan National Center for Biological Sciences of Bangalore (NCBS India, <https://www.ncbs.res.in/>)

Partner 4: Prof. Rajesh S. Gokhale National Institute of Immunology (NII, <http://www.nii.res.in/>)

Partner 5: Dr Dhiraj Kumar International Centre for Genetic Engineering and Biotechnology

Contacts CBI : Dr. Patrice Polard (Patrice.Polard@univ-tlse3.fr) et Nathalie Campo (Nathalie.Campo@univ-tlse3.fr) ; Dr. Isabelle Saves, Head of International Cooperation IPBS and CBI (Isabelle.Saves@ipbs.fr)